Event Abstract Back to Event A new identified CD20-spliced protein as potential target for T cell-based immunotherapy in B-cell lymphoma/leukemia patients Charline Vauchy1, 2, 3*, Clémentine Gamonet1, 2, 3, Etienne Daguindau3, 4, Carole Henry1, 2, Pierre Simon Rohrlich3, 4, Adotevi Olivier1, 2, 3, 4, Christophe Borg1, 2, 3, 4, Christophe Ferrand1, 2 and Yann Godet1, 3 1 Inserm, UMR1098, France 2 Etablissement Français du Sang, France 3 Université de Franche-Comté, France 4 Hopital Jean Minjoz, France CD20 is an antigen expressed on the cell surface of B lymphocytes. It is targeted by therapeutic monoclonal antibodies such as Rituximab in various B cell lymphomas and leukemias. We have identified an alternative transcript variant (ΔCD20) of the human MS4A1 lacking most of the transmembrane segments (Henry et al., Blood 2010). Whereas it was not detected in quiescent B lymphocytes from healthy donors, its expression is detectable in activated EBV infected B cells and in various B cell pathologies such as follicular lymphoma, chronic lymphocytic leukemia, diffuse large B-cell lymphoma and mantle cell lymphoma. In the present study we show that the Rituximab treatment of normal B lymphocytes or B-cell lymphomas induces the expression or overexpresses the ΔCD20 protein respectively. Thereby ΔCD20 could be an attractive target for T cell immunotherapy in association with Rituximab treatment. Thus, with a reverse immunology approach we sought to identify MHC-I and -II restricted epitopes derived from the ΔCD20 specific sequence. The HLA-A2/DRB1*0101 mouse model was used to identified a ΔCD20 specific epitope presented in the HLA-A*0201 context, and HLA-DR epitopes. ΔCD20 specific CD4+ T cell producing IFN-γ were also observed in lymphoma patients with various HLA class II contexts. Finally, isolated ΔCD20 specific CD4+ T cells clones are capable to induce autologous lymphoma B cell apoptosis after in vitro co-culture. These results identify ΔCD20 as an attractive target for T cell-based immunotherapy and Rituximab combination treatment for B cell lymphomas and leukemias. Acknowledgements This work has been supported by the Fondation de France and Ligue contre le Cancer. Keywords: Antigens, CD4-Positive T-Lymphocytes, Splicing, Lymphoma, Immunotherapy Conference: 15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013. Presentation Type: Abstract Topic: Adaptive Immunity Citation: Vauchy C, Gamonet C, Daguindau E, Henry C, Rohrlich P, Olivier A, Borg C, Ferrand C and Godet Y (2013). A new identified CD20-spliced protein as potential target for T cell-based immunotherapy in B-cell lymphoma/leukemia patients. Front. Immunol. Conference Abstract: 15th International Congress of Immunology (ICI). doi: 10.3389/conf.fimmu.2013.02.01196 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 12 Jul 2013; Published Online: 22 Aug 2013. * Correspondence: Miss. Charline Vauchy, Inserm, UMR1098, Besançon, France, charline.vauchy@edu.univ-fcomte.fr Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Charline Vauchy Clémentine Gamonet Etienne Daguindau Carole Henry Pierre Simon Rohrlich Adotevi Olivier Christophe Borg Christophe Ferrand Yann Godet Google Charline Vauchy Clémentine Gamonet Etienne Daguindau Carole Henry Pierre Simon Rohrlich Adotevi Olivier Christophe Borg Christophe Ferrand Yann Godet Google Scholar Charline Vauchy Clémentine Gamonet Etienne Daguindau Carole Henry Pierre Simon Rohrlich Adotevi Olivier Christophe Borg Christophe Ferrand Yann Godet PubMed Charline Vauchy Clémentine Gamonet Etienne Daguindau Carole Henry Pierre Simon Rohrlich Adotevi Olivier Christophe Borg Christophe Ferrand Yann Godet Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.
